BioDelivery: ~$2 Biopharma Stock On The Cusp Of A Turnaround
Today, we take a look at a small biopharma stock that might be on the cusp of a turnaround. Being a shareholder in BioDelivery Sciences has required a lot of patience over the past year, to say the least.
However, it does appear the stock has or is in the process of putting in a bottom. More importantly, 2017 is shaping up to be an inflection point that the market seems unaware of based on where the stock is currently trading.
However, it does appear the stock has or is in the process of putting in a bottom. More importantly, 2017 is shaping up to be an inflection point that the market seems unaware of based on where the stock is currently trading.